Paul Bunn, MD

Peled N, Zach L, Liran O, Ilouze M, Bunn PA Jr, Hirsch FR. Effective Crizotinib Schedule for Brain Metastases in ALK Rearrangement Metastatic Non-Small-Cell Lung Cancer. J Thorac Oncol. 2013 Dec;8(12):e112-3. PubMed PMID: 24389447

Miller YE, Vu KO, Kennedy TC, Hirsch FR, Petty TL, Bunn PA, Keith RL, Franklin WA, Wolf HJ, Prindiville S, Byers T. Lack of Association Between Sputum Atypia and Chronic Obstructive Pulmonary Disease Mortality. J Thoracic Oncol, 1(4):302-307, 2006.

Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA Jr, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC. Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer. PLoS One. 2013;8(12):e82236. PubMed PMID: 24349229

Cappuzzo F, Toschi L, Tallini G, Ceresoli G, Domenichini I, Bartolini S, Finocchiaro G, Magrini E, Metro G, Cancellieri A, Trisolini R, Crino L, Bunn, Jr. PA, Santoro A, Franklin WA, Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor I (IGFR-I) is significantly associated with longer survival in non-small cell lung cancer (NSCLC) patients treated with Gefitinib. Annals Oncology; 17: 1120-1127, 2006.

Dziadziuszko R, Witta SE, Cappuzzo F, Park S, Tanaka K, Danenberg PV, Baron AE, Crino L, Franklin WA, Bunn Jr., PA. Varella-Garcia M, Danenberg LD and Hirsch F. Epidermal Growth Factor Receptor Messenger RNA Expression, gene dosage and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res 12: 3078-3084, 2006.

Weiss G, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn L, Nguyen B, Paul S, McAndrews P, Bunn Jr., P, Kelly K. Elderly patients (= 70 years old) benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed versus docetaxel in patients with advanced non-small cell lung cancer previously treated with chemotherapy. J Clin Onc; 24(27): 4405-4411, 2006.

Bunn Jr., PA, Dziadziuszko R, Varella-Garcia M, Franklin WA, Witta SE, Kelly K, Hirsch FR. Biologic markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Cancer Res. 12 (12):3652-3656, 2006.

Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Baron A, Franklin WA, Hirsch FR, Geraci MW, Bunn PA, Jr. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res. 4 (8):521-8, 2006.

Dziadziuszko R, Holm B, Skov BG, Osterlind K, Sellers MV, Franklin WA, Bunn PA, Jr., Varella-Garcia M, Hirsch FR. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small cell lung cancer patients treated with chemotherapy. Annals Oncology. E-published ahead of print, 2006.

Bunn PA Jr, Franklin W, Doebele RC. The evolution of tumor classification: a role for genomics?. Cancer Cell. 2013 Dec 9;24(6):693-4. PubMed PMID: 24332038

Weiss, G. J., Rosell, R., Fosella, F., Perry, M., Stahel, R., Barata, F., Nguyen, B., Paul, S., McAndrews, P., Hanna, N., Kelly, K., Bunn, P. A., Jr. The impact of induction chemotherapy on the outcome of second-line therapy with Pemetrexed or Docetaxel in patients with advanced non-small-cell lung canger. Ann Oncol, in press. 2006.

Shepherd FA, Bunn PA, Paz-Ares L. Lung cancer in 2013: state of the art therapy for metastatic disease. Am Soc Clin Oncol Educ Book. 2013;33:339-46. PubMed PMID: 23714542

Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok T, Popat S, Bauman J, Nieva J, Novello S, Ou SH, Camidge DR. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer. 2013 Jul 1;119(13):2383-90. PubMed PMID: 23585220

Hirsch FR, Varella-Garcia M, Bunn PA, Jr., Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol; 24(31), 5034-42, 2006.

Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA Jr, Pao W. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res. 2013 May 1;19(9):2584-91. PubMed PMID: 23515407

Peled N, Barash O, Tisch U, Ionescu R, Broza YY, Ilouze M, Mattei J, Bunn PA Jr, Hirsch FR, Haick H. Volatile fingerprints of cancer specific genetic mutations. Nanomedicine. 2013 Aug;9(6):758-66. PubMed PMID: 23428987

Helfrich, B. A., Raben, D., Varella-Garcia, M., Gustafson, D., Chan, D. C., Coldren, C., Baron, A., Zeng, C., Franklin, W. A., Hirsch, F. R., Gazdar, A., Minna, J., Bunn, P. A., Jr. Antitumor activity of the EGFR tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in NSCLC cell lines and xenografts correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Can Research 12:(23), 7117-7125. 2006.

Mascaux C, Feser WJ, Lewis MT, Barón AE, Coldren CD, Merrick DT, Kennedy TC, Eckelberger JI, Rozeboom LM, Franklin WA, Minna JD, Bunn PA, Miller YE, Keith RL, Hirsch FR. Endobronchial miRNAs as biomarkers in lung cancer chemoprevention. Cancer Prev Res (Phila). 2013 Feb;6(2):100-8. PubMed PMID: 23268837

Dziadziuszko, R., Siemiatkowska, A., Limon, J., Rzyman, W., Jassem, J., Bunn, P. A., Jr., Varella-Garcia, M, Hirsch, F. R. Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: A case report. JTO 2:(1), 91-92. 2007.

Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA, Jr., Carbone DP. Mass spectrometry to predict clinical outcome for NSCLC patients treated with EGFR TKIs: A multi-cohort cross institutional study. JNCI, in press, 2007.

Lynch TJ, Adjei AA, Bunn PA Jr., Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Janne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res 12 (14): 4365s-4371s, 2006.

Weiss GJ, Bunn PA, Jr., Camidge DR. From radiotherapy to targeted therapy: 20 years in the management of non-small-cell lung cancer. Oncol 20 (12): 1515-1524, 2006.

Scarborough HA, Bunn PA Jr, DeGregori J. Personalized one-two punches for lung cancer. Cell Res. 2014 Dec 30. [Epub ahead of print] PubMed PMID: 25547118

Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R. Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 2014 Dec 1;32(34):3824-30. PubMed PMID: 25349291

Taguchi F, Solomon B Gregorc V, Kasahara K, Nishio M, Grigorieva J, Hunsucker SW, Duncan M, Hirsch FR, Bunn Jr., PA, Caprioli RM, Roder H, Carbone DP. Serum proteomic profiles for predicting response to gefitinib, a cross-laboratory technical validation study. Proc. AACR. 47: #2852, 2006.

Solomon B, Gregorc V, Taguchi F, Kasahara K, Nishio M, Roder H, Hirsch FR, Duncan MW, Bunn, Jr. PA, Carbone DP. Prediction of clinical outcome in non-small cell lung cancer (NSCLC) patients treated with gefitinib using Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) of serum. Proc. ASCO. J Clin Oncol 24: #7004, 2006.

Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer. 2014 Oct 1. [Epub ahead of print] PubMed PMID: 25273224

Hirsch FR, Franklin WA, McCoy J, Cappuzzo F, Varella-Garcia M, Witta SE, Gumerlock P, West H, Gandara DR, Bunn Jr., PA. Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal. Proc. ASCO. J clin Oncol 24: #7072, 2006.

Varella-Garcia M, Mitsudomi T, Yatabe Y, Kasaka T, Nakajima E, Franklin W, Bunn Jr., PA, Hirsch FR. EGFR genomic gain in Japanese non-small cell lung cancer patients treated with gefitinib. Proc. ASCO. J Clin Oncol 24: # 7164, 2006.

Dziadziuszko R, Holm B, Skov BG, Osterlind K, Franklin WA, Varella-Garcia M, Bunn, Jr. PA, Hirsch FR. Prognostic significance of EGFR FISH and IHC in non small-cell lung cancer patients treated with chemotherapy alone. Proc. ASCO. J Clin Oncol 24: #7193, 2006.

Nakajima E, Helfrich B, Chan D, Zhang Z, Hirsch FR, Chen V, Ma D, Bunn Jr. PA: Enzastaurin, a protein kinase Cbeta-selective inhibitor, inhibits the growth of SCLC and NSCLC cell lines. Proc. ASCO. J Clin Oncol 24: #13138, 2006.

Johnson DH, Schiller JH, Bunn PA. Reply to A. Braillon. J Clin Oncol. 2014 Nov 1;32(31):3575. PubMed PMID: 25225428

Hirsch FR, Bunn PA Jr, Herbst RS. "Companion diagnostics": has their time come and gone?. Clin Cancer Res. 2014 Sep 1;20(17):4422-4. PubMed PMID: 25059519

Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 May 21;311(19):1998-2006. PubMed PMID: 24846037

Chan DC, Chen VJ, Zhang Z, Helfrich B, Hirsch FR, Ma D, Bunn Jr. PA: Studies of pemetrexed and gemcitabine, alone and in combinations, in human lung cancer models. Proc. ASCO. J Clin Oncol 24(18S):#17114, 2006.

Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA Jr, Camidge DR, Tan AC, Hirsch FR, Heasley LE. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res. 2014 Jun 15;20(12):3299-309. PubMed PMID: 24771645

Bunn PA Jr, Hirsch FR, Aisner DL. Is there clinical value to prognostic signatures in early-stage NSCLC?. Clin Cancer Res. 2014 Apr 1;20(7):1727-9. PubMed PMID: 24583801

Johnson DH, Schiller JH, Bunn PA Jr. Recent clinical advances in lung cancer management. J Clin Oncol. 2014 Apr 1;32(10):973-82. PubMed PMID: 24567433

Hirsch FR, Bunn PA Jr. Progress in research on screening and genetics in lung cancer. Lancet Respir Med. 2014 Jan;2(1):19-21. PubMed PMID: 24461890

Hirsch, F.R., Bunn, P.A., Jr., Kato, H., Mulshine, J.L. (eds.). Textbook of Prevention and Detection of Early Lung Cancer. Taylor & Francis, 2006

Hirsch FR, Varella-Garcia M, Franklin WA, Bunn Jr. PA; Reply to Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 24(7): 1220-1, 2006.

Paz-Ares LG, Zimmermann A, Ciuleanu T, Bunn PA, Antonio BS, Denne J, Iturria N, John W, Scagliotti GV. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer. 2017 Feb;104:45-51. PubMed PMID: 28212999

Bunn PA Jr. Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. J Clin Oncol. 2017 Jan 10;35(2):243-252. PubMed PMID: 28056194

He Y, Bunn PA, Zhou C, Chan D. KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer. Oncotarget. 2016 Dec 13;7(50):82104-82111. PubMed PMID: 27893413

Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA, Jr. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol, in press, 2007.

Scarborough HA, Helfrich BA, Casás-Selves M, Schuller AG, Grosskurth SE, Kim J, Tan AC, Chan DC, Zhang Z, Zaberezhnyy V, Bunn PA, DeGregori J. AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. Clin Cancer Res. 2016 Sep 23. [Epub ahead of print] PubMed PMID: 27663586

Miller, Y. E., Blatchford, P., Hyun, D. S., Keith, R. L., Kennedy, T. C., Wolf, H., Byers, T., Bunn, P. A. Jr., Lewis, M. T., Franklin, W. A., Hirsch, F. R., Kittelson, J. Bronchial epithelial Ki-67 index is related to histology, smoking and gender but not lung cancer or chronic obstructive pulmonary disease. Cancer Epidemiol Biomarkers Prev, 16(11):2425-2431, 2007.

Frederick B., Helfrich B., Coldren C.,. Zheng D., Chan D, Bunn P.A., Jr, Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small-cell lung cancer. Mol Cancer Ther 6:(6), 2007.

Suda K, Bunn PA Jr, Rivard CJ, Mitsudomi T, Hirsch FR. Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench. J Thorac Oncol. 2017 Jan;12(1):27-35. PubMed PMID: 27642065

Hirsch FR, Suda K, Wiens J, Bunn PA Jr. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016 Sep 3;388(10048):1012-24. PubMed PMID: 27598681

Helfrich BA, Kim J, Gao D, Chan DC, Zhang Z, Tan AC, Bunn PA Jr. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther. 2016 Oct;15(10):2314-2322. PubMed PMID: 27496133

Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA Jr, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol. 2016 Jul;11(7):946-63. PubMed PMID: 27229180

Varella-Garcia M., Miller Y.E., Hirsch F.R., Mitchell J.D., Keith R.L. Baron A.E. Bunn P.A., Jr., Franklin W.A. Spectral karyotyping detects chromosome damage in bronchial cells of smokers and cancer patients. Am J Respir Crit Care Med,176:(5), 505-12, 2007.

Patil T, Aisner DL, Noonan SA, Bunn PA, Purcell WT, Carr LL, Camidge DR, Doebele RC. Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. Lung Cancer. 2016 Jun;96:27-32. PubMed PMID: 27133746

Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016 May;11(5):613-38. PubMed PMID: 27013409

Weiss G., Vokes E., Bunn P.A.,Jr., Magree, L., Rusk, J., Albert, D., Kelly, K. Docetaxel and Exisulind in previously treated non-cmall cell lung cancer (NSCLC) patients: A multicenter, phase II clinical trial. J Thor Oncol 2(10), 933-38, 2007.

Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. J Thorac Oncol. 2016 Apr;11(4):453-74. PubMed PMID: 26829312

Bunn PA Jr, Gaspar LE, Weyant MJ, Mitchell JD. Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer. Cancer. 2016 Mar 1;122(5):674-5. PubMed PMID: 26700372

Byers, T., Wolf, H. J., Franklin, W. A., Braudrick, S., Merrick, D. T., Shroyer, K. R., Hirsch, F. R., Zeng, C., Baron, A. E., Bunn, P. A., Miller, Y. E., Kennedy, T. C. Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity. Cancer Epidemiol Biomarkers Prev 17:(1), 158-162. 2008.

Hirsch FR, Dziadziuszko R, Varella-Garcia M, Thatcher N, Mann H, Watkins C, Parums D, Speake G, botwood N, Holloway B, Bunn PA, Jr., Franklin WA. Epidermal growth factor receptor immunohistochemistry: Comparison of antibodies and cut-off points to predict benefit from gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer. Clin Cancer, in press, 2008

266. Weiss, G. J., Bemis, L. T., Nakajima, E., Sugita, M., Birks, D. K., Robinson, W. A., Varella-Garcia, M., Bunn, P. A., Jr., Haney, J., Helfrich, B. A., Kato, H., Hirsch, F. R., Franklin, W. A. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Annals of Oncology, mdn006. 2008.

Steuer CE, Behera M, Berry L, Kim S, Rossi M, Sica G, Owonikoko TK, Johnson BE, Kris MG, Bunn PA, Khuri FR, Garon EB, Ramalingam SS. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer. 2016 Mar 1;122(5):766-72. PubMed PMID: 26695526

Weiss,G.J.; Zeng,C.; Kelly,K.; Tran,Z.V.; Bunn,P.A.,Jr. Single-Institution Experience with Pemetrexed and Bevacizumab as Salvage Therapy in Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer 8(5):335-338, 2007.

Merrick DT, Gao D, Miller YE, Keith RL, Baron AE, Feser W, Kennedy TC, Blatchford PJ, Braudrick S, Hirsch FR, Heasley L, Bunn PA Jr, Franklin WA. Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma. Cancer Prev Res (Phila). 2016 Jan;9(1):96-104. PubMed PMID: 26542061

Solomon, B.,Bunn, P. A., Jr. Adjuvant chemotherapy for non-small cell lung cancer. Cancer Invest 25:(4), 217-225. 2007.

Bunn, P. A., Jr. Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors? J Clin Oncol 25:(18), 2504-2505. 2007.

Aisner DL, Sholl LM, Berry L, Rossi M, Chen H, Fujimoto J, Moreira AL, Ramalingam S, Villaruz LC, Otterson GA, Haura EB, Politi K, Glisson BS, Cetnar J, Garon E, Schiller J, Waqar S, Sequist LV, Brahmer JR, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ. The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2017 Dec 7. [Epub ahead of print] PubMed PMID: 29217530

Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017 Nov 10;17(12):765. [Epub ahead of print] PubMed PMID: 29123245

Varella-Garcia M, Acheson K. Marshall GB, McCormarck RM, Rya A, Hirsch FR, Bunn Jr. PA, Hickinson DM, Speake G. Role of EGFR but not HER2 or HER3 gene copy number in predicting sensitivity of head and neck squamous cell carcinoma (SCCHN) cell lines to EGFR tyrosine kinase inhibitors. Proc. ASCO, J Clin Oncol 25, #6063, 2007.

Pacheco JM, Dimou A, Bunn PA. Advances in lung cancer. Oncotarget. 2017 Oct 3;8(45):78247-78248. PubMed PMID: 29108218

Solomon BJ, Roder H, Robert R, Taguchi F, Brahmer J, Joan SH, Duncan MW, Hirsch FR, Bunn Jr. PA, Carbone DP. Validation of preteomic classifier for clinical benefit from erlotinib as first line treatment for advanced non-small cell lung cancer (ECOG 3503). Proc. ASCO. J Clin Oncol 25: #7508, 2007.

Merrick DT, Dziadziuszko R, Szostakiewicz B, Szymanowska A, Rzyman W, Jassem E, Jassem J, Franklin WA, Bunn Jr. PA, Hirsch FR. High insulin-like growth factor 1 receptor (IGF 1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts). Proc. ASCO. J Clin Oncol 25: # 7550, 2007.

Hirsch FR, Varella-Garcia M, Bunn Jr. PA, Dziadziuszko R, Xiao Y, Gajapathy S, Skokan M, Lin M, Waring P, O’Neill V. Fluorescence in situ hybridization (FISH) subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in NSCLC. Proc. ASCO. J Clin Oncol 25: # 7570, 2007.

Dziadziuszko R, Hirsch FR, Varella-Garcia M, Thatcher N, Mann H, Watkins C, Speake G, Holloway B, Bunn Jr. PA, Franklin WA. Epidermal growth factor receptor (EGFR) immunohistochemistry. Comparison of antibodies (Abs) and cut points to predict benefit from gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer (NSCLC). Proc. ASCO. J Clin Oncol 25: # 7576, 2007.

Nakajima E, Sugita M, Dziadziuszko R, Tsuboi M, Kato H, Bunn Jr. PA, Franklin WA, Hirsch FR. Survival benefit of gefitinib treated non-small-cell lung cancer patients with exon 19 deletion mutations in epidermal growth factor receptor (EGFR) detected by a new sensitive PCR-based method. Proc. ASCO. J Clin Oncol 25: #10614, 2007.

Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017 Dec;17(12):725-737. PubMed PMID: 29077690

Pisters K, Vallieres E. Bunn Jr. PA, Crowley J, Chansky K, Ginsberg R, Gandara DR. Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (pc) chemotherapy in early stage non-small cell lung cancer (NSCLC). Follow-up on a phase III trial. Proc. ASCO J Clin Oncol 25: #7520, 2007.

Weiss GJ, Franklin WA, Bemis LT, Sugita M, Haney J, Bunn Jr. PA, Varella-Garcia M. HER2 and HER3 regulation in non-small cell lung cancer (NSCLC) associated with microRNAs (miRs) localized to 4q and 19q. Proc. AACR-Oncogenomics, Phoenix, AZ, 2007

Bunn Jr. PA, Helfrich BA, Zeng C, Baron A, Heasley A. FGF2 and FGFRs comprise an auxiliary autocrine pathway in non-small cell lung cancer cell lines. # 81, 15th SPORE Investigators? Workshop, Baltimore, MD, 2007.

Leonard SC, Lee H, Gaddy DF, Klinz SG, Paz N, Kalra AV, Drummond DC, Chan DC, Bunn PA, Fitzgerald JB, Hendriks BS. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. Anticancer Drugs. 2017 Nov;28(10):1086-1096. PubMed PMID: 28857767

Drabkin, H. A., Helfrich, B., Chan, D., Phang, T., Franklin, W. A., Bunn, P., Gemmill, R. M. Strategy to identify genes responsible for EGFR-inhibitor resistance and novel biomarkers in lung cancer. 15th SPORE Investigators' Workshop, July 7-10, 2007, Baltimore, MD. Proceedings . 2007.

Noonan SA, Patil T, Gao D, King GG, Thibault JR, Lu X, Bunn PA, Doebele RC, Purcell WT, Barón AE, Camidge DR. Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol. 2018 Jan;13(1):134-138. PubMed PMID: 28843358

Gera, L., Simkeviciene, V., Stewart, J. M., Chan, D. C., Bunn, P. A. N-(Fluorenyl-9-methoxycarbonyl)amino acid amide derivatives as a new class of anti-cancer agents. 20th American Peptide Society Symposium, June 26-30, 2007, Montreal, Quebec, Canada. Proceedings . 2007.

Heasley, L. E., Marek, L., Fritzsche, A., Helton, W. R., Nemenoff, R. A., McDermott, L. A., Helfrich, B., Bunn, P. A. Dominant FGF autocrine signaling in gefitinib-resistant non-small cell lung cancer cells. Experimental Biology 2008 meeting, April 5-9, 2008, San Diego, CA. Proceedings , Abstr #4192. 2008.

Helfrich, B., Bunn, P., McDermott, L. A., Heasley, L. FGF2 and FGFRs comprise an auxilliary autocrine pathway in NSCLC cell lines. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. J Thorac Oncol 2:(8 (Suppl 4)), S325. 2007.

Bunn PA Jr. Robert Comis, MD, The Passing of a "Lung Man". J Thorac Oncol. 2017 Aug;12(8):1323-1324. PubMed PMID: 28748814

Hirsch, F. R., Kittelson, J., Keith, R., Wolf, H., Lewis, M. T., Kennedy, T. C., Bunn, P. A., Byers, T. A., Miller, Y., Franklin, W. A. Predictive factors for preneoplasia in the bronchus. AACR's Advances and Challenges in Aerodigestive Epithelial Cancer Research: Genetics, Diagnosis, and Therapy Conference, February 6-9, 2007, Charleston, SC. Proceedings, Abstr #5629. 2007.

Pillai RN, Behera M, Berry LD, Rossi MR, Kris MG, Johnson BE, Bunn PA, Ramalingam SS, Khuri FR. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer. 2017 Nov 1;123(21):4099-4105. PubMed PMID: 28743157

Kabbinavar, F., Ross, H., Martins, R., Kelly, K., Camidge, D. R., Vokes, E., Wacker, B., Conlan, M., Hirsch, F., Bunn, P. Erlotinib (E) as a single agent or intercalated with carboplatin and paclitaxel (ECP) in an EGFR biomarker-enriched, previously untreated NSCLC population. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. J Thorac Oncol 2:(8 (Suppl 4)), S394. 2007.

Paz-Ares LG, Zimmermann A, Ciuleanu T, Bunn PA, Antonio BS, Denne J, Iturria N, John W, Scagliotti GV. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer. 2017 Feb;104:45-51. PubMed PMID: 28212999

Keith, R. L., Miller, Y. E., Jackson, M. K., Kittelson, J., Meisinger, V. G., Kelly, K., Hirsch, F., Franklin, W. A., Merrick, D., Bunn, P. A. Update on the use of oral iloprost for the chemoprevention of lung cancer. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. J Thorac Oncol 2:(8 (Suppl 4)), S330-S331. 2007.

Miller, Y. E., Hyun, D. S., Keith, R. L., Kennedy, T. C., Byers, T., Bunn, P. A., Franklin, W. A., Hirsch, F. Bronchial epithelial proliferation measured by Ki-67 is related to current smoking and sex but not to lung cancer or chronic obstructive pulmonary disease. 15th SPORE Investigators' Workshop, July 7-10, 2007, Baltimore, MD. Proceedings. 2007.

Nakajima, E., Sugita, M., Helfrich, B., Chan, D. C., Kato, H., Bunn, P. A. Jr., Franklin, W. A., Hirsch, F. R. Putative biomarker genes for pemetrexed treatment in small and non-small cell lung cancer cell lines, detected by microarray analysis. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. J Thorac Oncol 2:(8 (Suppl 4)), S508-S509. 2007.

Skokan, M. C., Gajapathy, S., Xiao, Y., Franklin, W. A., Hirsch, F. R., Bunn, P. A. Jr., Varella-Garcia, M. Epidermal growth factor receptor (EGFR) gene amplification in non-small cell lung cancer (NSCLC): Molecular patterns and sensitivity to tyrosine kinase inhibitors. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. J Thoracic Oncol 2:(8 (Suppl 4)), S323. 2007.

Bunn PA Jr. Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. J Clin Oncol. 2017 Jan 10;35(2):243-252. PubMed PMID: 28056194

Scarborough HA, Helfrich BA, Casás-Selves M, Schuller AG, Grosskurth SE, Kim J, Tan AC, Chan DC, Zhang Z, Zaberezhnyy V, Bunn PA, DeGregori J. AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. Clin Cancer Res. 2017 Mar 15;23(6):1531-1541. PubMed PMID: 27663586

Suda K, Bunn PA Jr, Rivard CJ, Mitsudomi T, Hirsch FR. Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench. J Thorac Oncol. 2017 Jan;12(1):27-35. PubMed PMID: 27642065

Spreafico, A., Gregorc, V., Dziadziuszko, R., Vigano, M., Giovannini, M., Duncan, M., Bunn, P. A., Villa, E., Hirsch, F. R. Serum E-cadherin does not associate with response to gefitinib in patients with non-small cell lung cancer (NSCLC). 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. J Thorac Oncol 2:(8 (Suppl 4)), -:S716. 2007.

Sugita, M., Nakajima, E., Kato, H., Bunn, P. A. Jr., Franklin, W. A., Hirsch, F. R. PCR method for detection of EGFR exon 19 deletion in NSCLC. American Association for Cancer Research Annual Meeting, April 14-18, 2007, Los Angeles, CA. Proc Am Assoc Cancer Res 48:(Suppl), -:Abstr #394. 2007.

Sugita, M., Nakajima, E., Kato, H., Bunn, P. A. Jr., Hirsch, F. R., Franklin, W. A. Sensitive PCR method detects EGFR exon19 deletions in NSCLC. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. J Thorac Oncol 2:(8 (Suppl 4)), S741. 2007.

Taguchi, F., Solomon, B., Gregorc, V., Heinrich, R., Gray, R., Kasahara, K., Nishi, M., Brahmer, J., Spreafico, A., Ludovini, V., Massion, P. P., Dziadziuszko, R., Schiller, J., Grigorieva, J., Tsypin, M., Hunsucker, S. W., Caprioli, R., Duncan, M. W., Hirsch, F. R., Bunn, P. A. Jr.et al. Prediction of benefit from EGFR TKIs b proteomic analysis of pretreatment serum. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. J Thorac Oncol 2:(8 (Suppl 4)), S167-S168. 2007.

Pacheco JM, Gao D, Smith D, Purcell WT, Hancock M, Bunn PA, Robin TP, Liu AK, Karam S, Gaspar LE, Kavanagh BD, Rusthoven CG, Aisner DL, Doebele RC, Camidge DR. Natural history and factors associated with overall survival in stage IV ALK rearranged non-small-cell lung cancer. J Thorac Oncol. 2018 Dec 29. [Epub ahead of print] PubMed PMID: 30599201

Weiss, G. J., Bemis, L. T., Sugita, M., Varella-Garcia, M., Haney, J., Bunn, P. A. Jr., Franklin, W. A. MicroRNAs predicted to regulate highly expressed genes in non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) are localized to 19q. American Association for Cancer Research Annual Meeting, April 14-18, 2007, Los Angeles, CA. Proc Am Assoc Cancer Res 48:(Suppl), Abstr #4517. 2007.

Weiss, G. J., Zeng, C., Kelly, K., Tran, Z. V., Bunn, P. A., Jr. Single-Institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. Clinical Lung Cancer 8:(5), 335-338. 2007.

Weiss, G. J., Hu, Z., Peake, D., Kelly, K., Bunn, P. A. Jr., Zhou, M., Sugita, M., Keith, R., Wong, D. T. Saliva mRNA expression profiling for early stage non-small cell lung cancer (NSCLC) Screening. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. J Thorac Oncol 2:(8 (Suppl 4)), S817. 2007

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol. 2018 Dec;13(12):1818-1831. PubMed PMID: 30268698

Witta, S. E., Hirsch, F. R., Lapadat, R., Dziadziuszko, R., Bunn, P. A. Jr. ErbB3 expression correlates with vorinostat and gefitinib activity and its coexpression with E-cadherin restores response to gefitinib in NSCLC. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. J Thorac Oncol 2:(8 (Suppl 4)), S445-S446. 2007.

Bunn PA Jr, Aisner DL. Broad-Based Molecular Testing for Lung Cancer: Precisely the Time for Precision. JAMA. 2018 Aug 7;320(5):445-446. PubMed PMID: 30087992

273. Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDeremott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA, Jr., Heasley LE. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 75: 196-207, 2009.

272. Varella-Garcia M, Mitsudomi T, Yatabe Y, Kosaka T, Nakajma E, Xavier AC, Skokan M, Zeng C, Franklin WA, Bunn PA, Jr., Hirsch FR. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thoracic Oncol 4: 318-25, 2009.

Bunn PA Jr, Dimou A. Systemic Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancers. J Clin Oncol. 2018 Sep 1;36(25):2571-2574. PubMed PMID: 30028655

271. Witta, S.E., Dziadziuszko, R., Lapadat, R., Hedman, K., Gemmill, R.M., Bunn, Jr. P.A., Hirsch, F.R. ErbB-3 expression is associated with E-cadherin and their co-expression restores response to gefitinib in non-small cell lung cancer (NSCLC). Annals of Oncology, in press, 2009.

270. Hirsch FR, Varella-Garcia M, Dziadziuszko R, Xiao Y, Gajapathy S, Skokan M, Lin M, O’Neil V, Bunn PA, Jr. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer res 14: 6317-23, 2008.

Merrick DT, Edwards MG, Franklin WA, Sugita M, Keith RL, Miller YE, Friedman MB, Dwyer-Nield LD, Tennis MA, O'Keefe MC, Donald EJ, Malloy JM, van Bokhoven A, Wilson S, Koch PJ, O'Shea C, Coldren C, Orlicky DJ, Lu X, Baron AE, Hickey G, Kennedy TC, Powell R, Heasley L, Bunn PA, Geraci M, Nemenoff RA. Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res. 2018 Sep 1;78(17):4971-4983. PubMed PMID: 29997230

269. Hickinson, D.M., Marshall, G., Beran, G., Varella-Garcia, M., Mills, E.A., South, M., Cassidy, A.M., Acheson, K., McWalter, G., McCormack, R., Bunn, Jr. P.A., French, T., Graham, A., Holloway, B.R., Hirsch, F.R., Speake, G. Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib. Mol Cancer Therapeutics, in press, 2008.

Patil T, Smith DE, Bunn PA, Aisner DL, Le AT, Hancock M, Purcell WT, Bowles DW, Camidge DR, Doebele RC. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol. 2018 Nov;13(11):1717-1726. PubMed PMID: 29981925

Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA Jr, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, Pérol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol. 2018 Aug 1;29(8):1701-1709. PubMed PMID: 29905778

Hirsch FR, Kerr KM, Bunn PA Jr, Kim ES, Obasaju C, Pérol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N. Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. Clin Lung Cancer. 2018 Jul;19(4):331-339. PubMed PMID: 29773328

268. Hirsch, F. R., Herbst, R. S., Olsen, C., Chansky, K., Crowley, J., Kelly, K., Franklin, W. A., Bunn, P.A., Jr., Varella-Garcia, M., Gandara, D. R. Increased EGFR gene copy number detected by FISH predicts outcome in non-small cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol, 26: 3351-57, 2008

He Y, Liu S, Mattei J, Bunn PA Jr, Zhou C, Chan D. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. Drug Des Devel Ther. 2018;12:981-986. PubMed PMID: 29731605

McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA Jr, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC. Resistance Mechanisms to Targeted Therapies in ROS1 ( ) and ALK ( ) Non-small Cell Lung Cancer. Clin Cancer Res. 2018 Jul 15;24(14):3334-3347. PubMed PMID: 29636358

267. Weiss, G. J., Bemis, L. T., Nakajima, E., Sugita, M., Birks, D. K., Robinson, W. A., Varella-Garcia, M., Bunn, P. A., Jr., Haney, J., Helfrich, B. A., Kato, H., Hirsch, F. R., Franklin, W. A. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Annals of Oncology, 19: 1053-59, 2008.

Hirsch FR, Sequist LV, Gore I, Mooradian M, Simon G, Croft EF, DeVincenzo D, Munley J, Stein D, Freivogel K, Sifakis F, Bunn PA Jr. Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP). Cancer. 2018 Jun 1;124(11):2407-2414. PubMed PMID: 29579334

266. Solomon, B., Helfrich, B, Zeng, C., Chansky, K., Nakajima, E., Gazdar, A. F., Gandara, D., Franklin, W. A., Hirsch, F. R., Duncan, M. W., Bunn, P. A., Jr., Hunsucker, S. W. Identification of putative biomarkers of gefitinib sensitivity in non-small cell lung cancer using difference gel electrophoresis (DIGE). Clin Can Research, submitted, 2008

Helfrich BA, Gao D, Bunn PA Jr. Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. Lung Cancer. 2018 Apr;118:148-154. PubMed PMID: 29571994

265. Hirsch FR, Dziadziuszko R, Thatcher N, Mann H, Watkins C, Parums D, Speake G, Holloway B, Bunn PA, Jr., Franklin WA. Epidermal growth factor receptor immunohistochemistry: Comparison of antibodies and cut-off points to predict benefit from gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer. Cancer 112:(5), 1114-1121, 2008.

Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2018 Mar 1;24(5):1038-1047. PubMed PMID: 29217530

264. Byers, T., Wolf, H. J., Franklin, W. A., Braudrick, S., Merrick, D. T., Shroyer, K. R., Hirsch, F. R., Zeng, C., Baron, A. E., Bunn, P. A., Miller, Y. E., Kennedy, T. C. Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity. Cancer Epidemiol Biomarkers Prev 17:(1), 158-162. 2008.

Bunn PA, Jr. Diseases Desperate Grown, JNCI 100: 520-521, 2008

127. Hirsch FR, Dziadziuszko R, Varella-Garcia M, Franklin WA, Gandara DR, Bunn PA, Jr. First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. J thorac Oncol 3: S138-42, 2008.

Noonan SA, Patil T, Gao D, King GG, Thibault JR, Lu X, Bunn PA, Doebele RC, Purcell WT, Barón AE, Camidge DR. Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol. 2018 Jan;13(1):134-138. PubMed PMID: 28843358

128. Einhorn LH, Bonomi P, Bunn PA, Jr., Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, West HJ, herbst RS. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. J thorax Oncol 3: 545-55, 2008

129. Bunn PA, Jr., Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options: more things to consider. Conclusion. Oncologists 13: 37-46, 2008.

Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA Jr, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Wakelee H, Thatcher N. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. J Thorac Oncol. 2018 Feb;13(2):165-183. PubMed PMID: 29175116

130. Bunn PA, Jr., Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer. Oncologist 13: 1-4, 2008,

Boyle TA, Khalil FK, Mino-Kenudson M, Sica GL, Moreira AL, Sholl LM, Knight MZ, Zhang L, Saller J, Varella-Garcia M, Berry LD, Chen H, Ellison KE, Rivard CJ, Kugler K, Wistuba II, Fujimoto J, Kwiatkowski DJ, Bunn PA, Kris MG, Haura EB, Hirsch FR. Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance. Appl Immunohistochem Mol Morphol. 2019 Nov 22. [Epub ahead of print] PubMed PMID: 31876606

320. Hirsch, F.R., Dziadziuszko, R., Camidge, D.R., Kabbinavar, F., Richardson, K., Richardson, F, Wacker, B., Franklin, W.A., Varella-Garcia, M., Bunn, Jr., P.A. Biomarker status correlates with clinical benefit: Phase 2 study of single-agent erlotinib (E) or E intercalated with carboplatin/paclitaxel (ECP) in an EGFR biomarker-selected NSCLC population. Submitted, 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology.

Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2019 Nov 21. [Epub ahead of print] PubMed PMID: 31859066

Mulshine JL, Ujhazy P, Antman M, Burgess CM, Kuzmin I, Bunn PA Jr, Johnson BE, Roth JA, Pass HI, Ross SM, Aldige CR, Wistuba II, Minna JD. From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. J Cell Biochem. 2019 Dec 5. [Epub ahead of print] PubMed PMID: 31803961

321. Camidge, D.R., Kabbinavar, F., Martins, R., Schnell, F., Witta, S., Eisen, T., Rusk, J., Wacker, B., Hirsch, F.R., Bunn, P. A. Jr. EGFR Biomarker-selected randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (C/P) in chemo-naïve advanced NSCLC. Submitted, 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology.

Keith RL, Blatchford PJ, Merrick DT, Bunn PA Jr, Bagwell B, Dwyer-Nield LD, Jackson MK, Geraci MW, Miller YE. A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers. Cancer Prev Res (Phila). 2019 Oct;12(10):721-730. PubMed PMID: 31308004

Guo R, Berry LD, Aisner DL, Sheren J, Boyle T, Bunn PA Jr, Johnson BE, Kwiatkowski DJ, Drilon A, Sholl LM, Kris MG. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. J Thorac Oncol. 2019 Sep;14(9):1666-1671. PubMed PMID: 31228623

Bunn PA Jr, Schenk E, Pacheco J, Dimou A. New Developments in Neoadjuvant Therapy for Lung Cancer. Oncology (Williston Park). 2019 Mar 13;33(3):101-6, 109. PubMed PMID: 30866032

322. Dziadziusko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Rzyman W, Jassem J, Bunn PA, Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor 1 (IGF1R) protein expression, mRNA expression and gene copy number in operable non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol, submitted, 2009.

El Osta B, Behera M, Kim S, Berry LD, Sica G, Pillai RN, Owonikoko TK, Kris MG, Johnson BE, Kwiatkowski DJ, Sholl LM, Aisner DL, Bunn PA, Khuri FR, Ramalingam SS. Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2019 May;14(5):876-889. PubMed PMID: 30735816

Pacheco J, Bunn PA. Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133. Clin Lung Cancer. 2019 May;20(3):148-160.e2. PubMed PMID: 30686680

323. Hirsch FR, Dziadziuszko R, Kabbinavar F, Camidge DR, Richardson K, Rusk J, Wacker B, Franklin WA, Varella-Garcia M, Bunn PA Jr. Randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (C/P) in chemo-naive advanced NSCLC: Biomarker status correlates with clinical benefit. Proc Am Soc Clin Oncol, in press, 2009.

324. Witta SE; Franekova V; Igolnikov I; Yoshida K; Coldren C; Frederick B; Varella-Garcia M; Bunn PA,Jr.; Hirsch FR. Synergistic effect of SNDX-275 with lapatinib or erlotinib in breast, lung or head and neck cancer cell lines expressing Her2. Proc Am Soc Clin Oncol, submitted, 2009.

325. Franekova V; Witta SE; Bunn PA,Jr.; Hirsch FR. The HDAC inhibitor SNDX-275 synergizes with erlotinib and induces mesenchymal to epithelial transition in pancreatic carcinoma. Proc Am Assoc Cancer Res, in press, 2009.

326. Conner A; Helfrich B; Chan DF; Bunn PA,Jr. EGFR expression confers resistance to IGF1R inhibition in ovarian cancer cell lines. Proc Am Assoc Cancer, submitted, 2009.

Schenk EL, Patil T, Pacheco J, Bunn PA Jr. 2020 Innovation Based Optimism for Lung Cancer Outcomes. Oncologist. 2020 Nov 11. [Epub ahead of print] PubMed PMID: 33179378

Bunn PA Jr. How gradual retirement has allowed me to spend more time with family and being physically active. Clin Adv Hematol Oncol. 2020 Jan;18(1):17-18. PubMed PMID: 32511217

272. Witta, S.E., Dziadziuszko, R., Lapadat, R., Hedman, K., Gemmill, R.M., Bunn, Jr. P.A., Hirsch, F.R. ErbB-3 expression is associated with E-cadherin and their co-expression restores response to gefitinib in non-small cell lung cancer (NSCLC). Annals of Oncology 20: 689-695, 2009.

Patil T, Pacheco JM, Dimou A, Purcell WT, Rossi C, Bunn PA, Doebele RC, Camidge DR, Ferrigno L. Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR -Mutant Non-small Cell Lung Cancer. Front Oncol. 2020;10:510. PubMed PMID: 32351892

Boyle TA, Khalil FK, Mino-Kenudson M, Sica GL, Moreira AL, Sholl LM, Knight MZ, Zhang L, Saller J, Varella-Garcia M, Berry LD, Chen H, Ellison KE, Rivard CJ, Kugler K, Wistuba II, Fujimoto J, Kwiatkowski DJ, Bunn PA, Kris MG, Haura EB, Hirsch FR. Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance. Appl Immunohistochem Mol Morphol. 2020 Oct;28(9):669-677. PubMed PMID: 31876606

Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 May;21(3):e191-e204. PubMed PMID: 31859066

Varella-Garcia M, Mitsudomi T, Yatabe Y, Kosaka T, Nakajma E, Xavier AC, Skokan M, Zeng C, Franklin WA, Bunn PA, Jr., Hirsch FR. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thoracic Oncol 4: 318-25, 2009.

Mulshine JL, Ujhazy P, Antman M, Burgess CM, Kuzmin I, Bunn PA Jr, Johnson BE, Roth JA, Pass HI, Ross SM, Aldige CR, Wistuba II, Minna JD. From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. J Cell Biochem. 2019 Dec 5. [Epub ahead of print] PubMed PMID: 31803961

Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDeremott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA, Jr., Heasley LE. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 75: 196-207, 2009.

Keith RL, Blatchford PJ, Merrick DT, Bunn PA Jr, Bagwell B, Dwyer-Nield LD, Jackson MK, Geraci MW, Miller YE. A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers. Cancer Prev Res (Phila). 2019 Oct;12(10):721-730. PubMed PMID: 31308004

Vallieres E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw P, Bunn, PA, Jr. International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cncer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 4: 1049-59, 2009.

Giroux DJ, Rami-Porta R, Chansky K, Crowley JJ, Groome PA, Postmus PE, Rusch V, Sculier JP, Shepherd FA, Sobin L, Goldstraw P, Bunn, PA, Jr. The IASLC Lung Cancer Staging Project: data elements for the prospective project. J Thorac Oncol 4:679-683, 2009.

Chansky K. Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P, Bunn PA, Jr. International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer Staging Project prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 4: 792-801, 2009.

Guo R, Berry LD, Aisner DL, Sheren J, Boyle T, Bunn PA Jr, Johnson BE, Kwiatkowski DJ, Drilon A, Sholl LM, Kris MG. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. J Thorac Oncol. 2019 Sep;14(9):1666-1671. PubMed PMID: 31228623

Kelly K, Kittelson J, Franklin WA, Kennedy TC, Klein CE, Keith RL, Dempsey EC, Jackson MK, Hirsch FR, Bunn PA, Miller YE. A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer. Cancer Prev Res 2: 440-449. 2009.

Bunn PA Jr, Schenk E, Pacheco J, Dimou A. New Developments in Neoadjuvant Therapy for Lung Cancer. Oncology (Williston Park). 2019 Mar 13;33(3):101-6, 109. PubMed PMID: 30866032

Gera L, Chan DC, Simkeviciene V, Bunn PA, Jr., Stewart JM. N-(Fluorenyl-9-methoxycarbonyl)amino acid amide derivatives as a new class of anti-cancer agents. Adv Exo Med Biol 611: 465-466, 2009.

El Osta B, Behera M, Kim S, Berry LD, Sica G, Pillai RN, Owonikoko TK, Kris MG, Johnson BE, Kwiatkowski DJ, Sholl LM, Aisner DL, Bunn PA, Khuri FR, Ramalingam SS. Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2019 May;14(5):876-889. PubMed PMID: 30735816

Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P, Bunn, PA, Jr. The IASLC lung cancer staging project: a proposal for a new international lymph node amp in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 4: 568-77, 2009.

Pacheco J, Bunn PA. Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133. Clin Lung Cancer. 2019 May;20(3):148-160.e2. PubMed PMID: 30686680

Vallieres E, Crowley JJ, Franklin W, Bunn P, Ginsberg RJ, Putnam JB, Chansky K, Gandara DR. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small cell lung cancer: Southwest Oncology ///group Trial S9900, an intergroup, randomized, phase III trial. In Press, J Clin Oncol 2010.

Bunn, PA, Jr. Novel therapies for non-small-cell lung cancer: a 2008 update. Clin Lung Cancer, suppl. 1: S6, 2009.

Hirsch FR, Bunn PA, Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol 10: 432-433, 2009.

Pacheco J, Schenk EL, Bunn PA. Optimal Therapy for Advanced Non-Small Cell Lung Cancer Without Driver Alterations. JNCI Cancer Spectr. 2021 Jun;5(3):pkab014. PubMed PMID: 34085000

Rolfo C, Meshulami N, Russo A, Krammer F, García-Sastre A, Mack PC, Gomez JE, Bhardwaj N, Benyounes A, Sirera R, Moore A, Rohs N, Henschke CI, Yankelevitz D, King J, Shyr Y, Bunn PA Jr, Minna JD, Hirsch FR. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. J Thorac Oncol. 2021 Nov 10. [Epub ahead of print] PubMed PMID: 34774792

Camidge R, Gaspar L, Goss G, Kelly K, Ramalingam S, Reckamp K, Simon G, Tsao M, West HJ, Herbst R, Johnson D, Bunn P, Govindan R. Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium. J Thorac Oncol 4: 930-935, 2009.

Pacheco J, Schenk EL, Bunn PA. Optimal Therapy for Advanced Non-Small Cell Lung Cancer Without Driver Alterations. JNCI Cancer Spectr. 2021 Jun;5(3):pkab014. PubMed PMID: 34085000

Dziadziusko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Rzyman W, Jassem J, Bunn PA, Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor 1 (IGF1R) protein expression, mRNA expression and gene copy number in operable non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol, J Clin Oncol 27: 388, 2009.

Hirsch FR, Dziadziuszko R, Kabbinavar F, Camidge DR, Richardson K, Rusk J, Wacker B, Franklin WA, Varella-Garcia M, Bunn PA Jr. Randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (C/P) in chemo-naive advanced NSCLC: Biomarker status correlates with clinical benefit. Proc Am Soc Clin Oncol, J Clin Oncol 27: 413, 2009.

Schenk EL, Patil T, Pacheco J, Bunn PA Jr. 2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist. 2021 Mar;26(3):e454-e472. PubMed PMID: 33179378

Bunn PA Jr. How gradual retirement has allowed me to spend more time with family and being physically active. Clin Adv Hematol Oncol. 2020 Jan;18(1):17-18. PubMed PMID: 32511217

Witta SE; Franekova V; Igolnikov I; Yoshida K; Coldren C; Frederick B; Varella-Garcia M; Bunn PA,Jr.; Hirsch FR. Synergistic effect of SNDX-275 with lapatinib or erlotinib in breast, lung or head and neck cancer cell lines expressing Her2. Proc Am Soc Clin Oncol, submitted, 2009.

Patil T, Pacheco JM, Dimou A, Purcell WT, Rossi C, Bunn PA, Doebele RC, Camidge DR, Ferrigno L. Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR -Mutant Non-small Cell Lung Cancer. Front Oncol. 2020;10:510. PubMed PMID: 32351892

Boyle TA, Khalil FK, Mino-Kenudson M, Sica GL, Moreira AL, Sholl LM, Knight MZ, Zhang L, Saller J, Varella-Garcia M, Berry LD, Chen H, Ellison KE, Rivard CJ, Kugler K, Wistuba II, Fujimoto J, Kwiatkowski DJ, Bunn PA, Kris MG, Haura EB, Hirsch FR. Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance. Appl Immunohistochem Mol Morphol. 2020 Oct;28(9):669-677. PubMed PMID: 31876606

Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 May;21(3):e191-e204. PubMed PMID: 31859066

Franekova V; Witta SE; Bunn PA,Jr.; Hirsch FR. The HDAC inhibitor SNDX-275 synergizes with erlotinib and induces mesenchymal to epithelial transition in pancreatic carcinoma. Proc Am Assoc Cancer Res, 2009.

Conner A; Helfrich B; Chan DF; Bunn PA,Jr. EGFR expression confers resistance to IGF1R inhibition in ovarian cancer cell lines. Proc Am Assoc Cancer, submitted, 2009.

Bunn PA, Jr. Signal transduction overview. Proceeding. J Thorac Oncol 4: S149, 2009

Pisters KM, Vallieres E, Bunn P, Crowley J, Chansky K, Gandara R. S9900 trial update, mature analysis. Procceding. J Thorac Oncol 4, S201, 2009.

Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, Raz DJ, Reckamp KL, Merritt RE, Owen DH, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doebele RC, Baciewicz F, Nagasaka M, Pass HI, Schulze K, Johnson A, Bunn PA, Johnson BE, Kris MG, Kwiatkowski DJ, Wistuba II, Chaft JE, Carbone DP, Lee JM. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022 Oct 8. [Epub ahead of print] PubMed PMID: 36369159

Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, Lozanski G, Pietrzak M, Seweryn M, Byun WY, Schulze K, Nicholas A, Johnson A, Grindheim J, Hilz S, Shames DS, Rivard C, Toloza E, Haura EB, McNamee CJ, Patterson GA, Waqar SN, Rusch VW, Carbone DP. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 2022 Oct;28(10):2155-2161. PubMed PMID: 36097216

Mack PC, Hirsch FR, Bunn PA, Minna JD. Longitudinal Analyses of COVID-19 Vaccination in Patients With Lung Cancer: Antibody Responses and Variant-Specific Neutralization. J Clin Oncol. 2022 Nov 20;40(33):3787-3789. PubMed PMID: 35759731

Mack PC, Gomez JE, Rodilla AM, Carreño JM, Hsu CY, Rolfo C, Meshulami N, Moore A, Brody RI, King JC, Treatman J, Lee S, Raskin A, Srivastava K, Gleason CR, de Miguel-Perez D, Tcheou J, Bielak D, Acharya R, Gerber DE, Rohs N, Henschke CI, Yankelevitz DF, Simon V, Minna JD, Bunn PA Jr, García-Sastre A, Krammer F, Shyr Y, Hirsch FR. Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer. Cancer Cell. 2022 Jun 13;40(6):575-577. PubMed PMID: 35504289

Peled N, Adams O, Koichi Y, Bunn P, Haick H, Hirsch FR. The unique “smell print” of NSCLC cell lines. Proceeding. J Thorac Oncol 4, S329, 2009

Keith RL, Kittelson JK, Blatchford P, Jackson M, Franklin WA, Hirsch FR, Minna J, Bunn PA, Miller YE. Oral Iloprost improves endobronchial dysplasia in former smokers. Proceeding, J Thorac Oncol 4: S380, 2009.

Patil T, Bunn PA. Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?. Clin Cancer Res. 2022 Jun 1;28(11):2204-2205. PubMed PMID: 35320359

Paz-Ares L, Spigel DR, Chen Y, Jove M, Juan-Vidal O, Rich P, Hayes T, Calderón VG, Caro RB, Navarro A, Dowlati A, Zhang B, Moore Y, Yao X, Kokhreidze J, Ponce S, Bunn PA. RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer. Cancer. 2022 May 1;128(9):1801-1811. PubMed PMID: 35195913

Smeltzer MP, Scagliotti GV, Wakelee HA, Mitsudomi T, Roy UB, Clark RC, Arndt R, Pruett CD, Kelly KL, Ujhazy P, Johnson ML, Eralp Y, Barrios CH, Barlesi F, Hirsch FR, Bunn PA. International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials. J Thorac Oncol. 2022 May;17(5):651-660. PubMed PMID: 35183774

Kavanagh BD, Adulrahman R, Camidge DR, Gerber DE, Bunn PA, Schiller J, Choy H, Gasper LE, Wu, J, King T, Timmerman RD. A pilot trial of erlotinib in combination with stereotactic body irradiation therapy (SBRT) for patients with recurrent non-small cell lung cancer (NSCLC). Proceeding, J Thorac Oncol 4: S590, 2009.

Witta SE, Girard L, Zheng D, Zhang Z, Minna J, Bunn PA, Jr., Chan D, Hirsch FR. Cetuximab activity in non-small cell lung cancer is enhanced in vivo by the HDAC inhibitor entinostat. Proceeding, J Thorac Oncol 4: S 597, 2009

Basu Roy U, Baird AM, Ciupek A, Fox J, Manley E Jr, Norris Xx K, Scagliotti GV, Wakelee HA, Mitsudomi T, Clark RC, Arndt R, Hirsch FR, Bunn PA, Smeltzer MP. Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer. JTO Clin Res Rep. 2022 Feb;3(2):100269. PubMed PMID: 34961851

Rolfo C, Meshulami N, Russo A, Krammer F, García-Sastre A, Mack PC, Gomez JE, Bhardwaj N, Benyounes A, Sirera R, Moore A, Rohs N, Henschke CI, Yankelevitz D, King J, Shyr Y, Bunn PA Jr, Minna JD, Hirsch FR. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. J Thorac Oncol. 2022 Feb;17(2):214-227. PubMed PMID: 34774792

Chan DC, Gupta M, Zhang Z, Zheng D, Sui X. Peters W. Bunn PA, Jr. Anti-tumor activity of ADH-1 in vitro and in vivo in combination with erlotinib (Tarceva) in lung cancer cell lines. Proceeding, J Thorax Oncol 4: S795, 2009.

Pacheco J, Schenk EL, Bunn PA. Optimal Therapy for Advanced Non-Small Cell Lung Cancer Without Driver Alterations. JNCI Cancer Spectr. 2021 Jun;5(3). PubMed PMID: 34085000

Chan DC, Zheng D, Zhang Z, Sui X, Tiffany T, Sugita M, Bunn Jr. PA. Roles of natural killer-cell immunoglobulin-like receptors (KIR) in immune escape and cancer metastasis. Proceeding, J Thorax Oncol 4: S900, 2009.

Schenk EL, Patil T, Pacheco J, Bunn PA Jr. 2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist. 2021 Mar;26(3):e454-e472. PubMed PMID: 33179378

Chan DC, Witta SE, Zheng D, Franekova V, Sui Z, Ordentlich P, Bunn PA, Jr., Hirsch FR. Characterization of the class 1 histone deacetylase inhibitor entinostat in EGFRi acquired resistance models and in combination with cetuximab in NSCLC. Proceeding AACR, April 2010.

Jonsson S, Moller YE, Kennedy TC, Varella-Garcia M, Skokan M, Wolf H, Feser W, Byers T, Haney J, Merrick D, Bunn PA, Jr., Keith RL, Hirsch FR, Franklin WA. Histological and molecular characteristics of twenty-nice cases of carcinoma in situ from a prospective bronchoscope cohort. Proceeding AACR, April 2010.

282. Pisters KM, Vallieres E, Crowley JJ, Franklin W, Bunn P, Ginsberg RJ, Putnam JB, Chansky K, Gandara DR. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small cell lung cancer: Southwest Oncology ///group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol 28: 1843-1849, 2010.

Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin HA. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett, October 25, 2010

285. Dziadziuszko R, Merrick DR, Witta SE, Mendoza AD, Szostakiewicx B, Szymanowska A, Rzyman W, Dziadziuszko K, Jassem J, Bunn PA, Jr., Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor 1 (IGF 1R) gene copy number is associated with survival in operable non-small- cell lung cancerL a comparison between IGF 1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 28: 2174-2180, 2010.

Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA, Jr. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitors therapy in non-small cell lung cancer. Lung Cancer January 2010

Bunn PA, Jr. Optimal therapy for elderly patients with early stage non-small cell lung cancere. Am J Respir Crit Care Med 181: 201-202, 2010

136. Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA Jr. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer 69: 1-12, 2010.

Chan DC, Witta SE, Zheng D, Franekova V, Sui Z, Ordentlich P, Bunn PA, Jr., Hirsch FR. Characterization of the class 1 histone deacetylase inhibitor entinostat in EGFRi acquired resistance models and in combination with cetuximab in NSCLC. Proceeding AACR, April 2010.

Dacic S, Travis WD, Giltnane JM, Kos F, Abel J, Hilz S, Fujimoto J, Sholl L, Ritter J, Khalil F, Liu Y, Taylor-Weiner A, Resnick M, Yu H, Hirsch FR, Bunn PA Jr, Carbone DP, Rusch V, Kwiatkowski DJ, Johnson BE, Lee JM, Hennek SR, Wapinski I, Nicholas A, Johnson A, Schulze K, Kris MG, Wistuba II. Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study. J Thorac Oncol. 2023 Dec 7. [Epub ahead of print] PubMed PMID: 38070597

Rodilla AM, Valanparambil RM, Mack PC, Hsu CY, Cagan J, Tavolacci SC, Carreño JM, Brody R, Moore A, King JC, Gomez JE, Rohs N, Rolfo C, Bunn PA Jr, Gerber DE, Minna JD, Krammer F, Ramalingam SS, García-Sastre A, Shyr Y, Ahmed R, Hirsch FR. Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer. Cancer Cell. 2023 Nov 13;41(11):1838-1840. PubMed PMID: 37863065

Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, Lozanski G, Pietrzak M, Seweryn M, Byun WY, Schulze K, Nicholas A, Johnson A, Grindheim J, Hilz S, Shames DS, Rivard C, Toloza E, Haura EB, McNamee CJ, Patterson GA, Waqar SN, Rusch VW, Carbone DP. Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 2024 Jan;30(1):303. PubMed PMID: 37816821

Dacic S, Travis W, Redman M, Saqi A, Cooper WA, Borczuk A, Chung JH, Glass C, Lopez JM, Roden AC, Sholl L, Weissferdt A, Posadas J, Walker A, Zhu H, Wijeratne MT, Connolly C, Wynes M, Bota-Rabassedas N, Sanchez-Espiridion B, Lee JJ, Berezowska S, Chou TY, Kerr K, Nicholson A, Poleri C, Schalper KA, Tsao MS, Carbone DP, Ready N, Cascone T, Heymach J, Sepesi B, Shu C, Rizvi N, Sonett J, Altorki N, Provencio M, Bunn PA Jr, Kris MG, Belani CP, Kelly K, Wistuba I. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. J Thorac Oncol. 2023 Oct;18(10):1290-1302. PubMed PMID: 37702631

Jonsson S, Franklin WA, Varella-Garcia M, Kennedy TC, Merrick D, Matney KD, Oskarsdottir GN, Saemundsson A, Keith RL, Bunn PA, Miller YE. Prevalence, molecular markers, and outcome of bronchial squamous carcinoma in situ in high-risk subjects. APMIS. 2023 Oct;131(10):513-527. PubMed PMID: 37608782

Jonsson S, Moller YE, Kennedy TC, Varella-Garcia M, Skokan M, Wolf H, Feser W, Byers T, Haney J, Merrick D, Bunn PA, Jr., Keith RL, Hirsch FR, Franklin WA. Histological and molecular characteristics of twenty-nice cases of carcinoma in situ from a prospective bronchoscope cohort. Proceeding AACR, April 2010.

Peled N, Hakim M, Haick H, Bunn PA, Miller YE, Kennedy TC, Mitchell JD, Weyant MJ, Hirsch FR. Use of a nanoparticle-based artificial olfactory system, NaNose to distinguish malignant from benign pulmonary nodules. Proceeding, ASCO # 10521, 2010.

Varella-Garcia M, Cho Y, Lu X, Baron AE, Terracciano L, Camidge DR, Bunn PA, Franklin WA, Cappuzzo F, Doebele RC. ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC). Proceeding, ASCO # 10533, 2010.

Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, Lang C, Hoetzenecker K, Schwendenwein A, Boettiger K, Bunn PA Jr, Renyi-Vamos F, Schelch K, Prosch H, Byers LA, Hirsch FR, Dome B. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023 Nov-Dec;73(6):620-652. PubMed PMID: 37329269

Hirsch FR, Wynes MW, Gandara DR, Bunn PA, Jr. The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res 16: 49-9-4911, 2010

Bunn PA Jr., Hirsch FR, Doebele RC, Camidge DR, Varella-Garcia M, Franklin W. Biomarkers are here to stay for clinical research and standard care. J Thorac Oncol 5: 1113 – 1115, 2010.

Hirsch FR, Mok TS, Borges V, Bunn PA Jr. Molecularly targeted therapy: when to stop and when to continue? Lancet Oncol 11: 709-711, 2010.

Bunn PA Jr. Optimal therapy for elderly patients with early stage non-small cell lung cancer. Am J Respir Crit Care Med 181: 201-202, 2010

Rafnar T, Sulem P, Besenbacher S, Gudbjartsson DF, Zanon C, Gudmundsson J, Stacey SN, Kostic JP, Thorgeirsson TE, Thorleifsson G, Bjarnason H, Skuladottir H, Gudbjartsson T, Isaksson HJ, Isla D, Murillo L, Garcia-Prats MD, Panadero A, Aben KK, Vermeulen SH, van der Heijden HF, Feser WJ, Miller YE, Bunn PA, Kong A, Wolf HJ, Franklin WA, Mayordomo Jl, Kiemeney LA, Jonsson S, Thorsteinsdottir U, Stefansson L. Genome-wide significant association between a sequence variant at 15q15.2 and lung cancer risk. Cancer Res. 71: 1356-1361, 2011.

Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TCY, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy. J Clin Oncol. 2023 May 20;41(15):2682-2690. PubMed PMID: 37196429

Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garret-Mayer E, Bunn PA, Drabkin HA. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett 300: 66-78, 2011.

Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, Franklin WA, Mao J, Wilson DO, Merrick DT, Hirsch FR, Kennedy TC, Bunn PA Jr., Geraci MW, Miller YE. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res 365: 793-902, 2011.

Langston J, Patil T, Ross Camidge D, Bunn PA, Schenk EL, Pacheco JM, Jurica J, Waxweiler TV, Kavanagh BD, Rusthoven CG. CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer. Lung Cancer. 2023 Apr;178:103-107. PubMed PMID: 36809719

Wang S, Rong R, Yang DM, Fujimoto J, Bishop JA, Yan S, Cai L, Behrens C, Berry LD, Wilhelm C, Aisner D, Sholl L, Johnson BE, Kwiatkowski DJ, Wistuba II, Bunn PA Jr, Minna J, Xiao G, Kris MG, Xie Y. Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer. J Clin Invest. 2023 Jan 17;133(2). PubMed PMID: 36647832

Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA Jr., Camidge DR. A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 29: 3567-3573, 2011.

Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, Raz DJ, Reckamp KL, Merritt RE, Owen DH, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doebele RC, Baciewicz F, Nagasaka M, Pass HI, Schulze K, Johnson A, Bunn PA, Johnson BE, Kris MG, Kwiatkowski DJ, Wistuba II, Chaft JE, Carbone DP, Lee JM. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 Mar;165(3):828-839.e5. PubMed PMID: 36369159

Barash O, Peled N, Tisch U, Bunn PA Jr, Hirsch FR, Haick H. Classification of lung cancer histology by gold nanoparticle sensors. Nanomedicine, October 25, 2011.

Bunn PA Jr, Doebele RC. Genetic testing for lung cancer: reflex verusus clinical selection. J Clin Oncol 29: 1943-1945, 2011.

Doebele RC, Sumey C, Maxson DA, Lu X, Baron AB, Bunn PA, Varella-Garcia M, Aisner DL, Franklin WA, Camidge DR. Oncogene Status in Lung Adenocarcinomas Predicts patterns of metastatic spread. Proceeding IASLC WCLC 2011.

Barash O, Peled N, Tisch U, Bunn PA Jr, Hirsch FR, Haick H. Classification of lung cancer histology by gold nanoparticle sensors. Nanomedicine, 8: 580-589, 2012.

Witta SE, Jotte RM, Konduri K, Neubauer MA, Spisa AI, Ruxer RL, Varella-Garcia M, Bunn Jr. PA, Hirsch FR. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small cell lung cancer who progressed on prior chemotherapy. JCO 30: 2248-2255, 2012.

Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA Jr, Baron AE, Franklin WA, Aisner DL, Varella-Garcia M, Camidge DR. Oncogene status predicts patterns of metastatic spread in treatment-naïve nonsmall cell lung cancer. Cancer , 118: 4502-4510, 2012.

Casas-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA, Jr., Chan DC, Tan AC, DeGregori J. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res 72: 4154-4164, 2012.

Peled N, Hakim M, Bunn PA, Jr., Miller YE, Kennedy TC, Mattel J, Mitchell JD, Hirsch FR, Haick H. Non-invasive breath analysis of pulmonary nodules. J Thorac Oncol 7: 1528-1533, 2012

Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA, Jr., Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thoracic Oncol 7: 1807 – 1814, 2012

Hirsch FR, Bunn PA, Jr. A new generation of EGFR tyrosine-kinase inhibitors in NSCLC. Lancet Oncol 13: 442-443, 2012

Distinguished Professor, Medicine-Medical Oncology

Medical School

Undergraduate School

Internship

Residency

Fellowships

Languages

Department

Professional Titles

Recognitions

Research Interests

Publications

Professional Memberships

Practice Locations

Specialty Information

School of Medicine

CU Anschutz

Fitzsimons Building